GLP‐1 receptor agonists: Bridging diabetes, obesity, and periodontitis—A scoping review of emerging evidence
GLP-1-Rezeptoragonisten: Verbindung zwischen Diabetes, Adipositas und Parodontitis – Scoping-Review zu neuen Evidenzen
Journal of Periodontology · 2026-06 · 97 (6) · 1243-1256
DOI: 10.1002/jper.70092 ↗Auf einen Blick
Das Scoping-Review fand mechanistische und präklinische Hinweise auf einen möglichen Zusammenhang von GLP-1-Rezeptoragonisten mit Entzündungswegen der Parodontitis. Humanstudien sind bisher limitiert und indirekt.
Fragestellung
Welche Effekte von GLP-1-Rezeptoragonisten auf Parodontitis werden in der Literatur berichtet, mit Fokus auf Mechanismen und klinische Implikationen?
Methode
Scoping-Review nach PRISMA; Suche in Medline/PubMed und Embase nach präklinischen und klinischen englischsprachigen Studien zu GLP-1-Rezeptoragonisten und parodontalem Gewebe.
Ergebnisse
Mechanistische und präklinische Studien stützen eine biologisch plausible Verbindung zu Entzündung und Wirtantwort. Humanstudien sind begrenzt und beobachten Assoziationen zwischen Parodontitis und veränderten Inkretinprofilen, inkl. niedrigerem endogenen GLP-1 und Anstieg nach Parodontalbehandlung.
Einschränkungen
Humanstudien waren nur indirekt und insgesamt unzureichend für einen Nachweis eines therapeutischen Nutzens.
Schlussfolgerung der Autor:innen
Die Autor:innen sehen zunehmende mechanistische und präklinische Evidenz für mögliche Interaktionen mit parodontalen Entzündungswegen, aber noch keinen Nachweis eines therapeutischen Nutzens.
Kernaussagen
- Mechanistische und präklinische Daten sprechen für eine biologische Plausibilität.
- Humanstudien sind bislang selten und beobachtend.
- Für klinische Endpunkte fehlen kontrollierte Studien.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Scoping Review in der Zeitschrift Journal of Periodontology, online erschienen am 19.02.2026. Verfasst von Angeliki Polymeri und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Periodontitis, Obesity, Diabetes Mellitus. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: GUM (Sunstar Suisse SA, Etoy, Switzerland).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) are analogs of the endogenous incretin hormone GLP‐1 and are increasingly used in the treatment of diabetes and obesity. Beyond glycemic control and weight loss, they have demonstrated anti‐inflammatory, antioxidative, and immunomodulatory properties. Given the inflammatory nature of periodontitis and its bidirectional relationship with diabetes mellitus, interest is growing in exploring the potential therapeutic benefits of GLP‐1 RAs in periodontal diseases. This scoping review aims to search the existing literature on the effects of GLP‐1 RAs on periodontitis, focusing on underlying mechanisms and emerging clinical implications.
Methods
Following PRISMA guidelines for scoping reviews, a comprehensive search was conducted in Medline/PubMed and Embase to identify preclinical and clinical studies in English evaluating the effects of GLP‐1 RAs on periodontal tissues. Data were synthesized thematically to highlight key findings and gaps.
Results
Evidence from mechanistic and preclinical studies supports a biologically plausible link between GLP‐1 RAs and pathways central to periodontal inflammation and host response. Human studies remain limited and observational but consistently report associations between periodontitis and altered incretin hormone profiles, including reduced endogenous GLP‐1 levels and increases following periodontal treatment.
Conclusion
This scoping review identifies growing mechanistic and preclinical evidence suggesting potential interactions between GLP‐1 RAs and periodontal inflammatory pathways. Although current human evidence is indirect and insufficient to establish therapeutic benefit, these early signals highlight an important opportunity for future research. Well‐designed clinical trials with periodontal endpoints are needed to clarify whether GLP‐1 RAs may provide adjunctive value in periodontal care. Plain language summary GLP‐1 receptor agonists are medications commonly used to manage diabetes and obesity. In addition to their metabolic effects, laboratory and animal studies suggest that these drugs may influence biological processes also involved in gum disease, such as inflammation, immune response, and bone metabolism. This scoping review examined all available scientific studies on the relationship between GLP‐1 receptor agonists and periodontal disease. Most of the existing evidence comes from mechanistic and preclinical research showing that these medications can reduce inflammation and support tissue repair in experimental models. Human studies are still very limited and have focused mainly on metabolic markers rather than on direct measures of gum health. So far, no clinical trial has tested whether GLP‐1 medications can improve periodontal outcomes. Although no conclusions can be made for clinical dental practice today, the findings highlight an emerging and promising area of research. Well‐designed clinical studies are needed to determine whether GLP‐1 receptor agonists could eventually play a role in periodontal treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, Massachusetts, USA.
- Department of Periodontology, ACTA - Academic Centre for Dentistry Amsterdam, University of Amsterdam and Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Förderung
- GUM (Sunstar Suisse SA, Etoy, Switzerland)
Zitieren
APA
Polymeri, A., Feres, M., Giannobile, W. V., & Loos, B. G. (2026). GLP‐1 receptor agonists: Bridging diabetes, obesity, and periodontitis—A scoping review of emerging evidence. Journal of Periodontology, 97(6), 1243-1256. https://doi.org/10.1002/jper.70092
Vancouver
Polymeri A, Feres M, Giannobile WV, Loos BG. GLP‐1 receptor agonists: Bridging diabetes, obesity, and periodontitis—A scoping review of emerging evidence. Journal of Periodontology. 2026;97(6):1243-1256. doi:10.1002/jper.70092
BibTeX
@article{Polymeri2026,
author = {Polymeri, Angeliki and Feres, Magda and Giannobile, William V and Loos, Bruno G},
title = {GLP‐1 receptor agonists: Bridging diabetes, obesity, and periodontitis—A scoping review of emerging evidence},
journal = {Journal of Periodontology},
year = {2026},
volume = {97},
number = {6},
pages = {1243--1256},
doi = {10.1002/jper.70092}
}
EUVIMED